Browse the corpus

REFERENCES Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest , 2012, 141(2 Suppl):7-47. [PubMed 22315257 ] Suvarna R, Pirmohamed M, and Henderson L, “Possible Interaction Between Warfarin and Cranberry Juice,” BMJ , 2003, 327(7429):1454. [PubMed 14684645 ] Tàssies D, Freire C, Pijoan J, et al, “Pharmacogenetics of Acenocoumarol: Cytochrome P450 CYP 2C9 Polymorphisms Influence Dose Requirements and Stability of Anticoagulation,” Haematologica , 2002, 87(11):1185-91. [PubMed 12414349 ] Teichert M, van Schaik RH, Hofman A, et al, “Genotypes Associated With Reduced Activity of VKORC1 and CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial Treatment Period,” Clin Pharmacol Ther , 2009, 85(4):379-86. [PubMed 19225451 ] Thijssen HH, Janssen GM, and Baars LG, “Lack of Effect of Cimetidine on Pharmacodynamics and Kinetics of Single Oral Doses of R- and S-Acenocoumarol,” Eur J Clin Pharmacol , 1986, 30(5):619-23. [PubMed 3758150 ] Thijssen HH, Flinois JP, and Beaune PH, “Cytochrome P4502C9 is the Principal Catalyst of Racemic Acenocoumarol Hydroxylation Reactions in Human Liver Microsomes,” Drug Metab Dispos , 2000, 28(11):1284-90. [PubMed 11038154 ] Touloupidis S, Zoumpos I, Kalaitzis C, et al, “Acenocoumarol Associated Priapism: Report of a Case,” Andrologia , 2004, 36(1):47-9. [PubMed 14871265 ] Topic 9159 Version 39.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]